To augment the antitumor activity of ta-scFv bsAbs, Ahmed et al.38 constructed an engineered ta-scFv molecule composing of a scFv anti-body targeting the carbohydrate epitope on …

Aug 2, 2018 · Blinatumomab, a CD19/CD3 bispecific antibody (bsAb) designed in the BiTE (bispecific T-cell engager) format, is approved by the US Food and Drug Administration for the …

A single-chain variable fragment (scFv) is not actually a fragment of an antibody, but instead is a fusion protein of the variable regions of the heavy (V H) and light chains (V L) of …

Sep 4, 2015 · Through molecular cloning and/or phage expression library, high affinity recombinant single-chain Fv fragment (scFv) has been produced. This led to the development …

Apr 16, 2021 · Bispecific T cell engagers (BiTEs) represent a novel class of immunotherapeutic agents. BiTEs are fusion proteins that consist of two antibody single-chain variable fragments …

Dec 7, 2017 · We have developed a novel CD19/CD3 bsAb in the 100 kDa single chain-Fv Fc format (19/3-scFv-Fc). With a half-life of approximately 7 days, 19/3-scFv-Fc may be suitable …

To date, generation of single-chain fragment variable (scFv) has become an established technique used to produce a completely functional antigen-binding fragment in bacterial …

Sep 5, 2019 · Bispecific T-cell engaging antibodies (BiTES), comprising dual anti-CD3 and anti-tumor antigen scFv fragments, are important therapeutic agents for the treatment of cancer. …

In one bispecific antibody format, single-chain variable fragments (scFv) are linked to or inserted in different locations of an intact immunoglobulin G (IgG) molecule to confer dual epitope binding.

Dec 20, 2019 · Here, we circumvent the complications of domains’ fusion by designing scFv mutants that stabilize interaction between scFv and its target, thereby rescuing scFv efficacy. …